Fulya Yasan

Fulya Yasan has extensive experience in pharmacovigilance and risk management, currently serving as the Global Risk Management Therapeutic Area Lead at Bristol Myers Squibb since March 2018, with a focus on immunology, cardiovascular, and neuroscience. Prior to this role, Fulya held various positions at Celgene, including Associate Director of Pharmacovigilance and Lifecycle Management Quality and Head of Country Pharmacovigilance, from November 2011 to March 2018. Fulya's career began at Eli Lilly and Company, where roles included Senior Manager of Drug Safety and Medical Information. Educated at Istanbul University, Fulya earned a Master’s degree in Pharmacology and a Bachelor's degree in Pharmacy with 1st honors.